Episodes
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/vmat2-inhibitors-in-tardive-dyskinesia-9799
Summary
Tardive dyskinesia (TD) is a syndrome characterized by various iatrogenic movement disorders resulting from dopamine receptor antagonism. These movement disorders include akathisia, dystonia, buccolingual stereotypy, chorea, tics, and other abnormal involuntary movements, most commonly emerging after prolonged antipsychotic use.Vesicular monoamine transporter type 2 (VMAT2) inhibitors are now available in the United States for managing dyskinesia syndromes, each with a slightly different range of approved indications. VMAT2 inhibitors are agents that cause a depletion of neuroactive peptides such as dopamine in nerve terminals and are used to treat chorea due to neurodegenerative diseases or dyskinesias due to neuroleptic medications (tardive dyskinesia).
In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic discuss the structural and pharmacokinetic differences between these agents, understanding how they modulate dopamine levels at hypersensitive D2 receptors, common in TD. The program emphasizes the importance of VMAT2 inhibition and its interaction with antipsychotic medications.This podcast was recorded and is being used with permission of the presenters.
Examine the pharmacologic differences between the various VMAT2 inhibitors
Learning Objective
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.50 hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported by an educational grant from Neurocrine Biosciences.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
Missing episodes?
-
The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:
1. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. Discussion by:
Guest:
Muthiah Vaduganathan, MD
Co-Director of the Center for Cardiometabolic Implementation Science
Brigham and Women’s Hospital.2. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening– NEJM 2024. Discussion by:
Guest:
Mathew Clark, MD
Clinical Professor at the Sidney Kimmel medical college of
Thomas Jefferson University
Associate Director Family Medicine Residency Program
Jefferson Health - Abington3. Mindfulness Meditation vs Escitalopram for Treatment of Anxiety Disorders
Secondary Analysis of a Randomized Clinical Trial. JAMA Network Open Discussion by:
Guest:
Kim Alfonzo, MD
Resident– Family Medicine Residency Program
Jefferson Health – AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA.
This Podcast Episode does not offer CME/CE Credit.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/dare-to-move-beyond-symptom-improvement-schizophrenia-9781Summary
Detection – The importance of early detection and intervention in reducing the burden of schizophrenia and increasing recovery chances.Adherence – Shared decision-making for optimal medication choice, focusing on balancing efficacy and minimizing adverse effects that can lead to nonadherence (e.g., sedation, weight gain).Recovery – Functional recovery, quality of life, and achieving personal life goals as key outcomes in treatment.Engagement – Supporting patients in leading purposeful and meaningful lives.
Schizophrenia is a chronic and debilitating mental illness that significantly affects not only the health, well-being, and functioning of patients but also their surrounding environment. Promoting resilience is essential for enhancing health as well as treating mental health issues. A fresh perspective on schizophrenia emphasizes early intervention, symptom enhancement, relapse prevention, functional advancement, and quality of life improvement. The importance of personalized care to improve functional outcomes for individuals living with the condition gain insights into the DARE approach:In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic discuss the DARE approach and how shifting the goals of schizophrenia treatment toward not just response and remission but full recovery and resilience, underscore a holistic approach to mental health.
Evaluate the latest advancements in functional domains for schizophrenia treatment.Discuss personalized treatment to improve functional outcomes for individuals living with schizophrenia.
Learning Objectives
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which does not include hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is not commercially funded.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:
1. Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. JAMA 2024. Discussion by:
Guest:
Stephen Salloway, MD
Director of Neurology and the Memory and Aging Program at Butler Hospital
Professor of Psychiatry and Professor of Neurology at the
Warren Alpert Medical School of Brown University.2. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity - (The SURMOUNT OSA Trial) – NEJM 2024. Discussion by:
Guest:
Atul Malhotra, MD
Professor of Pulmonary Critical Care & Sleep Medicine
Previous at the University of California, San Diego.3. Relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of the evidence. Journal of Infection July 2024. https://doi.org/10.1016/j.jinf.2024.106187 Discussion by:
Guest:
Anupriya Grover-Wenk, MD
Faculty– Family Medicine Residency Program
Jefferson Health – AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA.
This Podcast Episode does not offer CME/CE Credit.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/navigating-the-complexities-of-mixed-mood-states-9705
Summary
Mixed episode bipolar disorders are now referred to as "mixed features" they occur when a person experiences symptoms of depression and mania simultaneously, according to the latest edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM). This shift reflects a broader understanding of the condition. Understanding and distinguishing these mixed mood states across Bipolar I, Bipolar II, and MDD is crucial for accurate diagnosis and management. Additionally, reviewing existing evidence on the efficacy, tolerability, and safety of treatments tailored to these conditions is essential for optimizing patient outcomes.
In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic dive into the complexities of mixed mood states in Bipolar I, Bipolar II, and Major Depressive Disorder (MDD). These mixed states involve the simultaneous experience of both manic or hypomanic and depressive symptoms, creating a unique challenge for diagnosis and treatment. This podcast will distinguish these mixed mood states across different disorders and review the latest evidence on the efficacy, tolerability, and safety of treatments designed to manage these challenging conditions.
This podcast/webcast was recorded and is being used with permission of the presenters.Learning Objectives
Distinguish mixed mood states associated with Bipolar I, Bipolar II, and MDDReview existing evidence pertaining to efficacy and tolerability/safety of treatments for Bipolar I, Bipolar II, and MDD with mixed features
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which does not include hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is not commercially funded.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/tackling-residual-risk-in-ascvd-and-ckd-9653
Summary
Inflammation plays a pivotal role in both cardiovascular and chronic kidney disease, making it a crucial target for reducing patient risk. In this focused 15-minute podcast, our experts break down the latest insights into how inflammation drives these conditions and explore innovative approaches to managing it.Listen to Dr. Ridker as he will delve into the critical role of inflammation in cardiovascular and chronic kidney disease, with a focus on the predictive value of hsCRP as a biomarker for ASCVD and CKD risk. Dr. Ridker explores emerging strategies to address inflammation, and how these advancements could potentially reduce cardiovascular risk and improve patient outcomes.
Learning Objective
Recognize the role of hsCRP as a biomarker in evaluating the risk of ASCVD and CKDIdentify the role of current and emerging agents, based on their mechanism of action, to target inflammation and potentially reduce cardiovascular risk
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
Association of Black Cardiologists, Inc. (ABC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Association of Black Cardiologists, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and ABC. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which includes 0.25 hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported by an independent medical educational grant from Novo Nordisk.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
Integrate multidisciplinary management for patients with fibrosing ILDs to manage comorbidities and monitor for the need for specialty center referral
https://www.mycme.com/courses/circling-the-wagons-to-care-fibrosing-ilds-9649
Summary
Navigating the challenges of fibrosing ILDs requires a team approach. In this podcast, explore the "Dream Team" of healthcare professionals who collaborate to address the diverse needs of patients with IPF, SSc-ILD, and PPF. From pulmonologists to therapists and beyond, uncover the critical roles each plays in managing comorbidities, symptoms, and overall well-being. Gain valuable insights on when to refer to a specialized ILD center for comprehensive care.
Learning Objective
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours, which includes 0 hours of pharmacology.For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/major-depressive-disorder-interventions-for-remission-9634
Summary
The goal of treating major depressive disorder (MDD) is complete remission. Unfortunately, residual symptoms, such as anhedonia and cognitive impairment, are common in patients with MDD and contribute to worse outcomes. Tailoring antidepressant therapy to individual patients can help to mitigate residual symptoms and promote complete remission.In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic discuss the risk-benefit profiles of available antidepressants and their efficacy for residual depressive symptoms. The faculty review the relative burden of side effects with different agents, the impact of therapies on cognitive function, and specific approaches to managing anhedonia.
This podcast/webcast was recorded and is being used with permission of the presenters.
Discuss the risk–benefit profile of antidepressant medications and the potential impact on residual symptomsTailor MDD interventions to specific patient needs, based on the presence or risk of residual symptoms and using culturally sensitive communication, to achieve clinical remission
Learning Objectives
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.50 hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/primary-care-questions-on-moderate-to-severe-asthma-9617
Summary
Two experts from distinct clinical backgrounds – a primary care physician and a pulmonology PA – answer the top 5 questions primary care clinicians have about moderate-to-severe asthma. These questions come from clinician learners at Conversations in Primary Care (CPC) and Emerging Challenges and Clinical Updates in Primary Care (ECCU) live-virtual symposia from May through August, 2024.In just 15 minutes, this podcast/webcast covers the latest on:
New inhaler options: Albuterol/budesonide and smart therapy alternativesMontelukast: Weighing benefits against risks and boxed warningsBiomarkers: What to test and how to use the results to guide referralsBiologics: When to consider them and how to co-manage with specialistsPractical tips: Best practices for primary care clinicians in everyday asthma managementLearning Objectives
Evaluate patients with asthma to identify those with inflammatory phenotypes who are more likely to have exacerbations and severe diseaseEscalate care for patients with moderate-to-severe asthma uncontrolled on ICS-LABA
Upon completion of this activity, learners should be able to:This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours, which includes 0.25 hours of pharmacology.
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:
1. Physician Coaching by Professionally Trained Peers for Burnout and Well-Being. Jama Open Network 2024
Guest:
Susan Kuchera, MD
Program Director – Family Medicine Residency Program
Jefferson Health – Abington2. Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes/ Target Trial Emulation Using Real-World Data/ Annals of Internal Medicine
Guest:
Richard Potter, MD
Resident – Family Medicine Residency Program
Jefferson Health – Abington3. Counterfit Ozempic JAMA
Guest:
Jasmine Walker, MD
Resident – Family Medicine Residency Program
Jefferson Health – AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA.
This Podcast Episode does not offer CME/CE Credit.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:
1. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer’s disease: a randomized, controlled clinical trial. Alzheimer’s Research & Therapy https://doi.org/10.1186/s13195-024-01482-z (2024) 16:122
Guest:
Philip Lieberman, MD
Resident – Family Medicine Residency Program
Jefferson Health – Abington2. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
Guest:
Richard E. Pratley , MD
Medical Director at the AdventHealth Diabetes Institute
Senior Investigator, Diabetes Program Lead at the Translational Research Institute
3. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
Guest:
Richard Potter, MD
Resident – Family Medicine Residency Program
Jefferson Health – AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA.
This Podcast Episode does not offer CME/CE Credit.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
Identify ways to overcome provider and practice-based healthcare disparities in the management of patients with COPD
https://www.mycme.com/courses/impacting-copd-outcomes-challenges-and-opportunities-9534
Summary
Join Dr. Fernando Martinez as he welcomes Dr. David Au and Dr. Jamuna Krishnan to The NACE Clinical Highlights Show. This podcast highlights the research of Dr. Au and Dr. Krishnan, discussing the important translation of their research into pulmonology clinical practice.
Learning Objectives
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours, which includes 0 hours of pharmacology.For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
Discuss the biology of menopausal vasomotor symptoms (VMS)Integrate new and emerging agents into the treatment of women with menopausal VMS, based on patient characteristics and preferences
https://www.mycme.com/courses/dd5-your-questions-on-menopausal-vasomotor-symptoms-9542
Summary
Dr. Leana Wen guides Dr. Genevieve Neal-Perry through five of your most common questions on menopausal VMS. Get a better understanding of the evolution in the science surrounding the biology of menopause, and discuss new and emerging non-hormonal treatment options for women with menopausal hot flashes and night sweats. Keep the conversation going with this, the third podcast in the series.
Learning Objectives
Upon completion of this activity, learners should be able to:This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours, which includes 0 hours of pharmacology.For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported by an independent medical educational grant from Astellas Pharma Global Development, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
Review evolving concepts in the understanding, evaluation, and treatments of severe asthma and their implications on management
https://www.mycme.com/courses/a-better-understanding-advances-in-severe-asthma-9530
Summary
In this CME/CE podcast, join NACE and the Association for Pulmonary Advanced Practice Providers as Nurse Practitioner Corinne Young and Dr. Diego Maselli take a deep dive into the latest advances in severe asthma treatment. Join in a dynamic discussion on groundbreaking research into IL-13 agents and mucus production, TSLP, mast cell activity, and more. Discover the experts’ take on the latest evolutions in our understanding of asthma treatments, and gain practical insights into how these innovations are shaping clinical practice.
Learning Objectives
Upon completion of this activity, learners should be able to:This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours, which includes 0 hours of pharmacology.
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/recognizing-the-burden-of-residual-symptoms-in-mdd-9526
Summary
Early and effective treatment of major depressive disorder (MDD) is essential to prevent persistent residual symptoms, which are associated with worse outcomes. Evidence indicates that residual symptoms, such as impaired cognition, are underrecognized and undertreated in routine clinical care. Recognizing residual symptoms and the factors contributing to suboptimal treatment response is a critical first step to modifying management, with the goal of eliminating residual symptoms and achieving full remission.
In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic discuss common residual symptoms and other signs of suboptimal treatment response, including the impact of antidepressant side effects and the efficacy of antidepressants for residual symptoms.This podcast/webcast was recorded and is being used with permission of the presenters.
This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.25 hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
- Show more
